The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40

[1]  B. Robinson,et al.  The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 , 2014, BMC Cancer.

[2]  A. Nowak.  Immunological checkpoint inhibitors enter adolescence. , 2013, The Lancet. Oncology.

[3]  A. Currie,et al.  Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model , 2013, Journal of immunotherapy.

[4]  Michael R. Green,et al.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.

[5]  I. Dick,et al.  Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.

[6]  A. Tolcher,et al.  Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors , 2013, Oncoimmunology.

[7]  Sunil Singhal,et al.  Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery , 2012, Proceedings of the National Academy of Sciences.

[8]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[9]  D. Nelson.  Turning the tumor microenvironment into a self vaccine site , 2012, Oncoimmunology.

[10]  A. Nowak,et al.  The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer , 2012, International reviews of immunology.

[11]  B. Robinson,et al.  Programmed Death Ligand 2 in Cancer-Induced Immune Suppression , 2012, Clinical & developmental immunology.

[12]  D. Nelson,et al.  Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses , 2012, Cancer Immunology, Immunotherapy.

[13]  B. McCaughan,et al.  Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. , 2011, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[14]  J. Prieto,et al.  Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. , 2011, Cancer research.

[15]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[16]  C. Kurts,et al.  Cross-priming in health and disease , 2010, Nature Reviews Immunology.

[17]  M. Smyth,et al.  Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy1 , 2009, The Journal of Immunology.

[18]  A. Lew,et al.  Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. , 2008, International immunology.

[19]  R. G. van der Most,et al.  Targeting the Effector Site with IFN-αβ-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors1 , 2008, The Journal of Immunology.

[20]  R. G. van der Most,et al.  Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. , 2008, Journal of immunology.

[21]  J. Meyerhardt,et al.  Adjuvant Treatment of Colorectal Cancer , 2007, CA: a cancer journal for clinicians.

[22]  H. Schild,et al.  Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection , 2007, Clinical reviews in allergy & immunology.

[23]  R. G. van der Most,et al.  Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. , 2005, Cancer research.

[24]  P. Sinha,et al.  Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.

[25]  J. Frelinger,et al.  Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation1 , 2004, The Journal of Immunology.

[26]  S. Singhal,et al.  Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. , 2004, The Journal of thoracic and cardiovascular surgery.

[27]  J. Wigginton,et al.  Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1 , 2003, The Journal of Immunology.

[28]  R. Gelber,et al.  Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis , 2001, The Lancet.

[29]  B. Robinson,et al.  T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. , 1999, Cancer research.

[30]  S Oehen,et al.  Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. , 1998, Journal of immunology.

[31]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.